4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Imatinib 400 mg, or a second-generation TKI (dasatinib, nilotinib, bosutinib), or asciminib (ASC4FIRST; US accelerated approval for first-line use in October 2024, still conditional on confirmatory evidence). Choice by comorbidity and treatment goal; monitor BCR-ABL1 IS at 3, 6, 12 months against ELN milestones.
The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.
Dasatinib is a second-generation BCR::ABL1 pill that, combined with the immunotherapy blinatumomab, can put Ph-positive ALL into deep remission with no chemotherapy at all.
Nilotinib is a second-generation CML pill that produces deeper responses faster than imatinib, at the cost of cardiovascular and metabolic side effects.
Bosutinib is a CML pill with less cardiovascular and pleural toxicity than its rivals; its main side effect is diarrhoea.
Asciminib is a BCR::ABL1 blocker that binds a different pocket from every other approved TKI, given accelerated approval for newly diagnosed chronic-phase chronic myeloid leukaemia in 2024 and now being tested in Ph-positive ALL.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3/4 laboratory) · US label, 81 children with Ph+ ALL on dasatinib with chemotherapy (CA180372); 36% in adults with imatinib-resistant or -intolerant chronic phase CML on 100 mg alone | - | 96% |
| Pleural effusion · US label, newly diagnosed chronic phase CML, dasatinib arm (n=258, minimum 60 months follow-up); 24% of 135 adults with Ph+ ALL | 28% | 3% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Thrombocytopenia · US label, 556 patients with CML in asciminib trials (grade 3 in 7%, grade 4 in 10%) | 28% | 17% |
| Hypertension · US label, 556 patients with CML in asciminib trials (grade 3 in 10%, grade 4 in 0.2%) | 18% | 10.2% |
| Pancreatic enzyme elevation · US label, 556 patients with CML (grade 3 in 7%, grade 4 in 2%); pancreatitis in 2% | 20% | 9% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Switch TKI guided by mutation analysis; ponatinib or asciminib for T315I; allogeneic HSCT if two or more TKIs fail or in advanced phase.
Ponatinib is a BCR::ABL1 inhibitor that also blocks the T315I resistance mutation. In 2024 it gained accelerated US approval, with chemotherapy, for newly diagnosed Ph-positive ALL.
Asciminib is a BCR::ABL1 blocker that binds a different pocket from every other approved TKI, given accelerated approval for newly diagnosed chronic-phase chronic myeloid leukaemia in 2024 and now being tested in Ph-positive ALL.
Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.
Bosutinib is a CML pill with less cardiovascular and pleural toxicity than its rivals; its main side effect is diarrhoea.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Pancreatitis · US label, PhALLCON ponatinib arm; lipase elevations in 60% | 34% | 15% |
| Hypertension · US label, PhALLCON ponatinib arm (163 patients with newly diagnosed Ph+ ALL, with chemotherapy) | 34% | 14% |
| Arterial occlusive events · US label, PACE (449 patients with resistant CML or Ph+ ALL, 45 mg); 18% in OPTIC with response-based dose reduction and 6% in PhALLCON (newly diagnosed Ph+ ALL) | 26% | 14% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Thrombocytopenia · US label, 556 patients with CML in asciminib trials (grade 3 in 7%, grade 4 in 10%) | 28% | 17% |
| Hypertension · US label, 556 patients with CML in asciminib trials (grade 3 in 10%, grade 4 in 0.2%) | 18% | 10.2% |
| Pancreatic enzyme elevation · US label, 556 patients with CML (grade 3 in 7%, grade 4 in 2%); pancreatitis in 2% | 20% | 9% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Treatment-free remission attempt after more than 5 years of TKI (more than 4 for a second-generation drug) and more than 2 years of MR4 or better (ELN 2020 minimal criteria), with monthly PCR for the first six months; restart on loss of MMR. In EURO-SKI's interim analysis, molecular relapse-free survival was 50% at 24 months.
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.
TKI plus acute-leukaemia-type induction (ponatinib or dasatinib with chemotherapy), then allogeneic HSCT.
Ponatinib is a BCR::ABL1 inhibitor that also blocks the T315I resistance mutation. In 2024 it gained accelerated US approval, with chemotherapy, for newly diagnosed Ph-positive ALL.
Dasatinib is a second-generation BCR::ABL1 pill that, combined with the immunotherapy blinatumomab, can put Ph-positive ALL into deep remission with no chemotherapy at all.
Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Pancreatitis · US label, PhALLCON ponatinib arm; lipase elevations in 60% | 34% | 15% |
| Hypertension · US label, PhALLCON ponatinib arm (163 patients with newly diagnosed Ph+ ALL, with chemotherapy) | 34% | 14% |
| Arterial occlusive events · US label, PACE (449 patients with resistant CML or Ph+ ALL, 45 mg); 18% in OPTIC with response-based dose reduction and 6% in PhALLCON (newly diagnosed Ph+ ALL) | 26% | 14% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3/4 laboratory) · US label, 81 children with Ph+ ALL on dasatinib with chemotherapy (CA180372); 36% in adults with imatinib-resistant or -intolerant chronic phase CML on 100 mg alone | - | 96% |
| Pleural effusion · US label, newly diagnosed chronic phase CML, dasatinib arm (n=258, minimum 60 months follow-up); 24% of 135 adults with Ph+ ALL | 28% | 3% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.